WO2008087936A1 - 縮合テトラヒドロキノリン誘導体及びその医薬用途 - Google Patents

縮合テトラヒドロキノリン誘導体及びその医薬用途 Download PDF

Info

Publication number
WO2008087936A1
WO2008087936A1 PCT/JP2008/050349 JP2008050349W WO2008087936A1 WO 2008087936 A1 WO2008087936 A1 WO 2008087936A1 JP 2008050349 W JP2008050349 W JP 2008050349W WO 2008087936 A1 WO2008087936 A1 WO 2008087936A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical purposes
tetrahydroquinoline derivative
condensed tetrahydroquinoline
compound
condensed
Prior art date
Application number
PCT/JP2008/050349
Other languages
English (en)
French (fr)
Inventor
Masahiro Eda
Tomoko Kuroda
Keiichi Aritomo
Yoshiyuki Aoki
Satoshi Kaneko
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Priority to EP08703213A priority Critical patent/EP2116538B1/en
Priority to JP2008554034A priority patent/JP5328371B2/ja
Priority to US12/523,031 priority patent/US8367695B2/en
Publication of WO2008087936A1 publication Critical patent/WO2008087936A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

本発明の課題は、プロゲステロン受容体(PR)およびミネラルコルチコイド受容体(MR)等の他の核内受容体への作用が少なく、グルココルチコイド受容体(GR)選択的結合活性を有する化合物を提供することにある。 本発明は、下記式(I)（式中、各記号は明細書中の記載と同義である）で表される縮合テトラヒドロキノリン化合物又はその医薬上許容される塩、及びそれらの水和物を提供する。
PCT/JP2008/050349 2007-01-15 2008-01-15 縮合テトラヒドロキノリン誘導体及びその医薬用途 WO2008087936A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08703213A EP2116538B1 (en) 2007-01-15 2008-01-15 Condensed tetrahydroquinoline derivative and use thereof for medical purposes
JP2008554034A JP5328371B2 (ja) 2007-01-15 2008-01-15 縮合テトラヒドロキノリン誘導体及びその医薬用途
US12/523,031 US8367695B2 (en) 2007-01-15 2008-01-15 Condensed tetrahydroquinoline derivative and use thereof for medical purposes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007005472 2007-01-15
JP2007-005472 2007-01-15

Publications (1)

Publication Number Publication Date
WO2008087936A1 true WO2008087936A1 (ja) 2008-07-24

Family

ID=39635940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050349 WO2008087936A1 (ja) 2007-01-15 2008-01-15 縮合テトラヒドロキノリン誘導体及びその医薬用途

Country Status (5)

Country Link
US (1) US8367695B2 (ja)
EP (1) EP2116538B1 (ja)
JP (1) JP5328371B2 (ja)
TW (1) TWI410422B (ja)
WO (1) WO2008087936A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518892A (ja) * 2012-06-05 2015-07-06 ギリアド ファーマセット エルエルシー 抗ウイルス化合物の合成
JP2021532103A (ja) * 2018-07-20 2021-11-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換トリアゾロキノキサリン誘導体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106187879B (zh) * 2016-07-12 2018-08-28 华侨大学 一种含氮杂环化合物的还原方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019458A2 (en) 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO2000006137A2 (en) 1998-07-30 2000-02-10 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
WO2002064550A1 (en) 2001-02-14 2002-08-22 Abbott Laboratories Glucocorticoid receptor modulators
WO2003004028A1 (en) 2001-07-02 2003-01-16 Akzo Nobel N.V. Tetrahydroquinoline derivatives
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004110385A2 (en) 2003-06-11 2004-12-23 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6852719B2 (en) 2000-10-30 2005-02-08 Pfizer Inc. Glucocorticoid receptor modulators
WO2005087769A1 (en) 2004-03-09 2005-09-22 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
WO2006014394A1 (en) 2004-07-02 2006-02-09 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
WO2006019716A1 (en) 2004-07-14 2006-02-23 Ligand Pharmaceuticals, Inc. Intracellular receptor modulator compounds and methods
JP2007005472A (ja) 2005-06-22 2007-01-11 Sumitomo Electric Ind Ltd 基板の表面処理方法およびｉｉｉ−ｖ族化合物半導体の製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
US5688808A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6583180B2 (en) * 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019458A2 (en) 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JPH10510840A (ja) * 1994-12-22 1998-10-20 リガンド・ファーマシューティカルズ・インコーポレイテッド ステロイド受容体モジュレーター化合物および方法
WO2000006137A2 (en) 1998-07-30 2000-02-10 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
US6852719B2 (en) 2000-10-30 2005-02-08 Pfizer Inc. Glucocorticoid receptor modulators
WO2002064550A1 (en) 2001-02-14 2002-08-22 Abbott Laboratories Glucocorticoid receptor modulators
WO2003004028A1 (en) 2001-07-02 2003-01-16 Akzo Nobel N.V. Tetrahydroquinoline derivatives
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004110385A2 (en) 2003-06-11 2004-12-23 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
WO2005087769A1 (en) 2004-03-09 2005-09-22 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
WO2006014394A1 (en) 2004-07-02 2006-02-09 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
WO2006019716A1 (en) 2004-07-14 2006-02-23 Ligand Pharmaceuticals, Inc. Intracellular receptor modulator compounds and methods
JP2007005472A (ja) 2005-06-22 2007-01-11 Sumitomo Electric Ind Ltd 基板の表面処理方法およびｉｉｉ−ｖ族化合物半導体の製造方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BELANOF, BIOLOGICAL PSYCHIATRY., vol. 52, no. 5, 2002, pages 386 - 92
INVEST. OPHTHALMOL. VIS. SCI., vol. 37, 1996, pages 805 - 813
J. BIOL. CHEM., vol. 266, 1991, pages 18072 - 18081
MASAHIKO MIKUNI; SHINKEI SHINPO, ADVANCES IN NEUROLOGICAL SCIENCES, vol. 42, no. 4, 1998, pages 656 - 65
MURPHY, J PSYCHIATRY NEUROSCI., vol. 18, no. 5, November 1993 (1993-11-01), pages 209 - 213
NEUROIMMUNOMODULATION, vol. 1, 1994, pages 66 - 73
PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 10681 - 10685
See also references of EP2116538A4 *
SUZUKI ET AL.: "Organic Synthesis via Boranes", vol. 3, ALDRICH CHEMICAL COMPANY

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518892A (ja) * 2012-06-05 2015-07-06 ギリアド ファーマセット エルエルシー 抗ウイルス化合物の合成
JP2018145200A (ja) * 2012-06-05 2018-09-20 ギリアド ファーマセット エルエルシー 抗ウイルス化合物の合成
JP2021532103A (ja) * 2018-07-20 2021-11-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換トリアゾロキノキサリン誘導体
JP7336506B2 (ja) 2018-07-20 2023-08-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換トリアゾロキノキサリン誘導体

Also Published As

Publication number Publication date
EP2116538A1 (en) 2009-11-11
TW200831506A (en) 2008-08-01
TWI410422B (zh) 2013-10-01
US8367695B2 (en) 2013-02-05
JPWO2008087936A1 (ja) 2010-05-06
EP2116538A4 (en) 2011-03-16
EP2116538B1 (en) 2013-03-27
JP5328371B2 (ja) 2013-10-30
US20100063055A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2008009415A3 (de) 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
WO2008130953A3 (en) 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2008096829A1 (ja) ３環系化合物
WO2009002427A3 (en) Methods of synthesizing cinacalcet and salts thereof
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
IL213323A (en) Causes prevention and / or treatment of an allergic disease containing a low-molecular-weight acid derivative of polysulfate hyaluronic acid, its use or its acceptable medicinal salt, as well as a low-molecular-weight acid derivative of hyaluronic polysulfate and a pharmaceutical preparation containing it
WO2010004197A3 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
WO2009013545A3 (en) Chemical compounds
IL192403A0 (en) Fgf-receptor (fgfr)agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
IL213620A0 (en) Preparation and therapeutic applications of (2s, 3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl]-3,5-difluorobenzamide
WO2014085153A8 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
WO2008089093A3 (en) Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone
WO2009156837A3 (en) Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2008087936A1 (ja) 縮合テトラヒドロキノリン誘導体及びその医薬用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703213

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008554034

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008703213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12523031

Country of ref document: US